Systemic sclerosis associated myopathy.

[1]  M. Hudson,et al.  Capillary pathology with prominent basement membrane reduplication is the hallmark histopathological feature of scleromyositis , 2022, Neuropathology and applied neurobiology.

[2]  G. Espinosa,et al.  Clinico-pathological phenotypes of Systemic Sclerosis associated myopathy: analysis of a multicenter large cohort. , 2022, Rheumatology.

[3]  M. Nikpour,et al.  Using magnetic resonance imaging to map the hidden burden of muscle involvement in systemic sclerosis , 2022, Arthritis Research & Therapy.

[4]  C. Bonroy,et al.  Anti-RuvBL1/2 autoantibodies in patients with systemic sclerosis or idiopathic inflammatory myopathy and a nuclear speckled pattern , 2022, Annals of the Rheumatic Diseases.

[5]  L. Mouthon,et al.  Quantification of Antifibrillarin (anti-U3 RNP) Antibodies: A New Insight for Patients with Systemic Sclerosis , 2021, Diagnostics.

[6]  M. Hudson,et al.  Histopathological features of systemic sclerosis-associated myopathy: A scoping review. , 2021, Autoimmunity reviews.

[7]  H. Goebel,et al.  Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology , 2021, Acta Neuropathologica.

[8]  C. Campochiaro,et al.  The clinical phenotype of Systemic Sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. , 2021, Rheumatology.

[9]  Yan Du,et al.  Myopathy is a Risk Factor for Poor Prognosis of Patients with Systemic Sclerosis , 2020, Medicine.

[10]  D. Theodorou,et al.  Myocarditis in Scleroderma: An Underrecognized Manifestation of the Disease. , 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[11]  L. Mouthon,et al.  Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients. , 2019, Autoimmunity reviews.

[12]  R. Sauter,et al.  Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis , 2019, Annals of the rheumatic diseases.

[13]  F. Buttgereit,et al.  Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis. , 2018, Nutrition.

[14]  E. Svenungsson,et al.  Muscle endurance, strength, and active range of motion in patients with different subphenotypes in systemic sclerosis: a cross-sectional cohort study , 2018, Scandinavian journal of rheumatology.

[15]  Ami A. Shah,et al.  Association of Fibrosing Myopathy in Systemic Sclerosis and Higher Mortality , 2017, Arthritis care & research.

[16]  M. Cutolo,et al.  Histopathological findings in systemic sclerosis-related myopathy: fibrosis and microangiopathy with lack of cellular inflammation , 2017, Therapeutic advances in musculoskeletal disease.

[17]  E. Ballot,et al.  The Clinical Relevance of Antifibrillarin (anti‐U3‐RNP) Autoantibodies in Systemic Sclerosis , 2017, Scandinavian journal of immunology.

[18]  J. Paik,et al.  Myopathy in scleroderma and in other connective tissue diseases , 2016, Current opinion in rheumatology.

[19]  L. Hummers,et al.  Severity of muscle weakness independently associates with disability as measured by the Health Assessment Questionnaire‐Disability Index (HAQ‐DI) in scleroderma , 2016 .

[20]  M. Hudson,et al.  Clinical and Serologic Correlates of Anti‐PM/Scl Antibodies in Systemic Sclerosis: A Multicenter Study of 763 Patients , 2014, Arthritis & rheumatology.

[21]  M. Hudson,et al.  Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort , 2014, Scandinavian journal of rheumatology.

[22]  M. Fujimoto,et al.  Autoantibodies to RuvBL1 and RuvBL2: A Novel Systemic Sclerosis–Related Antibody Associated With Diffuse Cutaneous and Skeletal Muscle Involvement , 2014, Arthritis care & research.

[23]  U. Müller-Ladner,et al.  Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study , 2012, Annals of the rheumatic diseases.

[24]  L. Mouthon,et al.  Myopathies related to systemic sclerosis: a case–control study of associated clinical and immunological features , 2010, Scandinavian journal of rheumatology.

[25]  L. Mouthon,et al.  A descriptive and prognostic study of systemic sclerosis-associated myopathies , 2008, Annals of the rheumatic diseases.

[26]  L. Mouthon,et al.  Systemic Sclerosis‐Associated Myopathy , 2007, Annals of the New York Academy of Sciences.

[27]  U. Müller-Ladner,et al.  Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database , 2007, Annals of the rheumatic diseases.

[28]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[29]  C. Denton,et al.  SYSTEMIC SCLEROSIS , 2008 .